Showing 2741-2750 of 5621 results for "".
- Carl Zeiss Meditec Announces Investment in Early Stage MIGS Device Maker MicroOptxhttps://modernod.com/news/carl-zeiss-meditec-announces-investment-in-clinical-stage-migs-device-maker-microoptx/2476679/Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx, a privately held company focused on minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical tec
- New Survey Highlights Growing Insurance Problem That Delays Sight-Saving Carehttps://modernod.com/news/new-survey-highlights-growing-insurance-problem-that-delays-sight-saving-care/2476670/The majority of ophthalmologists in a new survey said that a cost-management tool required by health insurance companies is delaying or disrupting the sight-saving care they give their patients. The tool is called prior authorization. Insurance companies use it to control costs by reducing medica
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Awardhttps://modernod.com/news/valeda-light-delivery-system-receives-2019-medical-design-excellence-award/2476654/LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry Eyehttps://modernod.com/news/first-subject-enrolled-in-large-trial-to-confirm-safety-and-efficacy-of-dry-eye-treatment-device-tearcare/2476650/Sight Sciences announced the first subject has been enrolled in OLYMPIA, a US pivotal trial to further assess the safety and efficacy of TearCare for patients with dry eye disease. TearCare is a wearable, personalized, open-eye technology that delivers regu
- Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disordershttps://modernod.com/news/invitae-announces-id-your-ird-program-to-expand-access-to-genetic-testing-for-inherited-retinal-disorders/2476648/Invitae announced the launch of “ID YOUR IRD,” an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD). “Identifying the genetic cause of an inherit
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- Draper James and VSP Eyes of Hope Commit Nearly $4 Million to Fund Eye Care and Eyewear in Support of Young Womenhttps://modernod.com/news/draper-james-and-vsp-eyes-of-hope-commit-nearly-4-million-to-fund-eye-care-and-eyewear-in-support-of-young-women/2476637/More women than men are at risk for vision loss from eye diseases like glaucoma and macular degeneration. To help ensure more women have access to critical eye care, Draper James, the Southern-inspired lifestyle brand founded by Reese Witherspoon, announced a partne
- Three-Year Clinical Trial Results Support Iluvien Launch in Europe for Prevention of Relapse in Recurrent Noninfectious Uveitis Affecting the Posterior Segmenthttps://modernod.com/news/three-year-clinical-trial-results-support-iluvien-launch-in-europe-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis-affecting-the-posterior-segment/2476635/Alimera Sciences announced 3-year followup data from the phase 3 clinical trial for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). The data will support the company’s pla